The American Journal of Managed Care: Survival Gains in AML Shadowed by Lasting Morbidity A highly sensitive bone marrow test could double survival rates for some groups of younger adults with acute myeloid leukemia (AML) by helping doctors identify if they might relapse up to three months ... Umbilical cord blood stem cell microtransplantation combined with chemotherapy significantly prolonged disease-free survival (DFS) in patients with acute myeloid leukemia (AML) and high-risk ... Cure Today: Uproleselan Fails to Improve Survival in AML, Although Some Subgroups May Benefit Uproleselan did not significantly improve overall survival in the intent-to-treat population of relapsed/refractory AML patients.
Primary refractory AML patients showed a substantial survival benefit ... Uproleselan Fails to Improve Survival in AML, Although Some Subgroups May Benefit News Medical: Rising survival rates for AML patients over 65 after allogeneic hematopoietic stem cell transplant Rising survival rates for AML patients over 65 after allogeneic hematopoietic stem cell transplant Healio: Black race prognostic for shorter survival in AML regardless of cytogenetic profile Black race prognostic for shorter survival in AML regardless of cytogenetic profile The National Law Review: Moleculin Issues New Positive AML Overall Survival Data: Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...
